Singular Bio
acquired by InvitaeSan Francisco, US · Delaware corporation · 1 known investors
Genetic screening platform for early pregnancy, acquired by Invitae.
Founders & leadership
JH
Jones HywelNamed on SEC filing
Board
EC
Eli CasdinBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 1 round · 2019
▶$6.6MraisedFeb 2019 · 8 investors · Other Health CareRule 506(b)
▶$6.6MraisedFeb 2019 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Eli CasdinDirector
- Jones HywelExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $6.6M
- Minimum investment
- $1
- Sales commissions
- $400K
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Singular Bio do?
- Genetic screening platform for early pregnancy, acquired by Invitae.
- Who are Singular Bio's investors?
- Singular Bio's investors include Civilization Ventures Management, Llc.
- How much funding has Singular Bio raised?
- Singular Bio has disclosed $6.6M raised across 1 round.
- Who acquired Singular Bio?
- Singular Bio was acquired by Invitae.
- Where is Singular Bio headquartered?
- Singular Bio is headquartered in San Francisco, US.